Heart Attack Patients to Have Stem Cell Treatment
Posted on: Thursday, 9 November 2006, 15:01 CST
Heart attack patients are to have their own stem cells injected into their hearts within hours of a heart attack to see if the stem cells can limit damage that often leads to heart failure, in a pioneering trial to be held in the UK.
Patients brought to the London Chest Hospital and the Heart Hospital will be recruited for the study. A stem cell sample will be taken from the patient's bone marrow then the patient will receive the prepared cells into the blocked artery.
David Macauley, chief executive of the UK Stem Cell Foundation, which is supporting the study, said: "This is the first known project of its type in the UK to combine stem cell delivery to the heart with primary angioplasty - where the blocked arteries in heart attack patients are opened as quickly as possible."
When patients are admitted to hospital after a heart attack, they are usually treated with balloon angioplasty, in which a catheter is inserted through the groin and into the blocked coronary artery. A balloon is then inflated to reopen the artery. The stem cell injection will add a further stage to the treatment, to further limit the damage caused by the heart attack.
Dr Mathur, the co-designed of the study, said: "If we can demonstrate improvement in the quality of life of patients then this will be a significant step forward in the treatment of heart disease. Because the stem cells are taken from the patient themselves there are minimal ethical issues surrounding this procedure. There is also less likelihood of rejection complications."
Source: Datamonitor
Related Articles
- Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
- Tiny Probes Track Down, Attack Cancer Cells
- Analysis Showed No Increased Risk of Hospitalization in Patients When Adding a LABA to ICS Compared to ICS Alone
- Pfizer's High-Dose Lipitor Reduces Heart Attack Risk in Kidney Disease Patients
- BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients With Cutaneous T-Cell Lymphoma (CTCL)
- Heart Patients Benefit From Big Hospitals
- Introgen Announces Positive Phase 2 Clinical Trial Results With INGN 225 Immunotherapy in Patients With Small Cell Lung Cancer
- Data Show Geron's Telomerase Inhibitor Cancer Drug is Active Against Cancer Stem Cells From Multiple Myeloma Patients
- Wireless Patient Monitoring Promises Reduced Hospital Costs By Freeing Expensive Critical Care Areas
- Three Suspected Bird Flu Patients Quarantined in Thailand Hospital
User Comments (0)

RSS Feeds